Toward precision psychiatry in bipolar disorder: staging 2.0 by Salagre, Estela et al.
REVIEW
published: 29 November 2018
doi: 10.3389/fpsyt.2018.00641
Frontiers in Psychiatry | www.frontiersin.org 1 November 2018 | Volume 9 | Article 641
Edited by:
Johann Steiner,
Universitätsklinikum Magdeburg,
Germany
Reviewed by:
Hassan Rahmoune,
University of Cambridge,
United Kingdom
Yilang Tang,
Emory University, United States
*Correspondence:
Eduard Vieta
evieta@clinic.cat
Iria Grande
igrande@clinic.cat
Specialty section:
This article was submitted to
Molecular Psychiatry,
a section of the journal
Frontiers in Psychiatry
Received: 07 August 2018
Accepted: 13 November 2018
Published: 29 November 2018
Citation:
Salagre E, Dodd S, Aedo A, Rosa A,
Amoretti S, Pinzon J, Reinares M,
Berk M, Kapczinski FP, Vieta E and
Grande I (2018) Toward Precision
Psychiatry in Bipolar Disorder: Staging
2.0. Front. Psychiatry 9:641.
doi: 10.3389/fpsyt.2018.00641
Toward Precision Psychiatry in
Bipolar Disorder: Staging 2.0
Estela Salagre 1, Seetal Dodd 2,3,4, Alberto Aedo 1,5, Adriane Rosa 6,7,8, Silvia Amoretti 9,
Justo Pinzon 1, Maria Reinares 1, Michael Berk 2,3,4,10, Flavio Pereira Kapczinski 11,
Eduard Vieta 1* and Iria Grande 1*
1 Barcelona Bipolar Disorders Program, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS,
CIBERSAM, Barcelona, Spain, 2 IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, VIC,
Australia, 3Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia, 4Orygen, The National Centre of
Excellence in Youth Mental Health, Melbourne, VIC, Australia, 5 Bipolar Disorders Unit, Department of Psychiatry, School of
Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 6 Laboratory of Molecular Psychiatry, Hospital de Clínicas
de Porto Alegre, Porto Alegre, Brazil, 7 Postgraduate Program: Psychiatry and Behavioral Science, Universidade Federal do
Rio Grande do Sul (UFRGS), Porto Alegre, Brazil, 8Department of Pharmacology and Postgraduate Program: Pharmacology
and Therapeutics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil, 9 Barcelona Clínic
Schizophrenia Unit, Hospital Clinic de Barcelona, CIBERSAM, Barcelona, Spain, 10 Florey Institute for Neuroscience and
Mental Health, Parkville, VIC, Australia, 11Department of Psychiatry & Behavioral Neurosciences, Mcmaster University,
Hamilton, ON, Canada
Personalized treatment is defined as choosing the “right treatment for the right person
at the right time.” Although psychiatry has not yet reached this level of precision, we
are on the way thanks to recent technological developments that may aid to detect
plausible molecular and genetic markers. At the moment there are some models that
are contributing to precision psychiatry through the concept of staging. While staging
was initially presented as a way to categorize patients according to clinical presentation,
course, and illness severity, current staging models integrate multiple levels of information
that can help to define each patient’s characteristics, severity, and prognosis in a more
precise and individualized way. Moreover, staging might serve as the foundation to create
a clinical decision-making algorithm on the basis of the patient’s stage. In this review we
will summarize the evolution of the bipolar disorder staging model in relation to the new
discoveries on the neurobiology of bipolar disorder. Furthermore, we will discuss how
the latest and future progress in psychiatry might transform current staging models into
precision staging models.
Keywords: bipolar disorder, staging, biomarkers, personalized psychiatry, prevention
INTRODUCTION
Bipolar disorder is a chronic psychiatric condition characterized by mood swings with both
manic and depressive symptoms (1). Despite this general picture, bipolar disorder is a highly
heterogeneous condition regarding clinical presentation, response to treatment and functional
outcome (2, 3). Subsequent DSM and ICD versions have increasingly reflected this heterogeneity,
for instance, by adding diagnosis and course specifiers (4). Still, the focus of current systems of
classification remains largely cross-sectional and limited to clinical features (5). Moreover, these
criteria apply to people with established disorder, but miss people in the prodromal phases of the
illness (4).
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Emerging data points to the need of a broader approach
to bipolar disorder. There is increasing evidence that bipolar
disorder is a neuroprogressive disorder, meaning that longer
duration of the disease entails more pronounced changes at
the clinical and neuropathological level, which may lead to
treatment refractoriness and neuropsychological deficits (6, 7).
Moreover, several studies support the notion of a prodromal
stage before illness onset (8). In an attempt to introduce a
longitudinal perspective of the illness in the diagnostic process
which would include the earliest phases of bipolar disorder and
guide treatment and prognosis, some authors have suggested
incorporating the staging model in psychiatry (9–13).
The staging model is based on the concept that an illness
progresses following an identifiable temporal progression, from
at-risk or prodromal stages to chronic ones (10). Moreover,
considering the neuroprogressive course of psychiatric disorders,
the staging model assumes that treatment needs and response
may differ according to stage. While early stages of the disease
might show a better response to simpler treatment regimens,
chronic stages might need more complex treatments and still
show less clinical improvement (14). Consequently, defining the
stage in which the patient is located may help clinicians to choose
the treatment that is better adapted to the patient’s needs (14).
Additionally, the administration of a timely treatment precisely
adapted to the stage in which the patient is located might modify
or even prevent the progression to subsequent stages of the
disease (10).
The staging model in bipolar disorder has been in constant
development since its introduction in psychiatry. As new
evidence on bipolar disorder has emerged, staging models were
refined according to these new findings. In spite of this, experts
supporting the staging model still warn that this model gives a
standard vision of the progression of the disorder that might not
suit every patient (15, 16).
New advances in the field of biological markers (e.g.,
molecular and neuroanatomical markers of illness vulnerability
and/or progression), genetics (e.g., genetic markers or
pharmacogenomics) or computer science (e.g., machine
learning approaches) might provide current staging models
of a higher level of precision regarding diagnosis, prognosis,
and treatment choice (15, 16), allowing a more personalized
approach to the patient.
The aim of this review is to summarize the evolution of
the staging model in bipolar disorder in relation to the new
discoveries on the course and neurobiology of the disease.
Furthermore, we will discuss how the latest and ongoing
progresses in psychiatry might transform current staging models
into precision staging models.
THE EVOLUTION OF STAGING MODELS IN
BIPOLAR DISORDER
The Dawn of Staging in Psychiatry: Fava
and Kellner Staging Model (1993)
Fava and Kellner, in 1993, first proposed the application of the
concept of staging to psychiatric disorders (9), as staging had
shown to be useful in other complex diseases potentially severe
if untreated, such as diabetes mellitus, cardiovascular diseases
and neoplastic diseases. However, their staging model faced a
major limitation in psychiatry research, which was the dearth
of longitudinal studies assessing the progression of psychiatric
disorders and the scarce data available on prodromal symptoms.
As a result, the staging model proposed by Fava and Kellner
did not focus on the longitudinal course of bipolar disorder, but
described the different stages that can be seen in a manic episode
based on symptom severity (Table 1). Although their model
referred only to the manic phase of the disease, Fava and Kellner
provided the basis for future staging models in psychiatry.
The Spread of the Concept of Staging in
Psychiatry: McGorry et al. (10)
In 2006, McGorry and colleagues introduced a staging model
which highlighted the longitudinal course of psychiatric diseases
in the psychotic spectrum, also integrating mood disorders
(10). They underlined that the staging model does not imply
that every patient needs to go through every stage. The main
characteristic of McGorry and colleagues’ model is that it is
built on evidence on major psychiatric disorders jointly and not
exclusively on data on bipolar disorder. Importantly, compiling
evidence emerging from research on neurobiological correlates of
psychotic disorders, allowed McGorry and colleagues to go one
step forward and include some biological and endophenotypic
markers in the earlier stages of their model (Table 1). They
warned, though, that evidence on biological markers arose from
studies that evaluated patients with long-established disease,
raising the question whether these biological markers were
inherent to psychiatric disorders or a consequence of illness
duration.
They also incorporated some indicators of illness extent and
progression -that is, functioning and cognitive impairment-
in their staging model. They defended the importance of
addressing social adaptation when assessing patients, as they
noted that a person who already presents a great deal of collateral
academic or social damage at illness onset may be less likely to
respond to treatment and hence is more prone to have a worse
prognosis. McGorry and colleagues have continued to progress
a transdiagnostic staging model, arguing that the early stages
are non-specific, although the later courses of different major
psychiatric disorders can have divergent course and outcome
patterns (17).
New Insights on Bipolar Disorder
Progression: Berk et al. (11)
Although similar to and adapting from McGorry and colleagues’
model (10), Berk and colleagues’ model focused exclusively
on bipolar disorder (11). At that moment, a growing body
of evidence on a prodromal state for bipolar disorder started
to appear (11). Besides identifying risk factors for bipolar
disorder, mainly a positive family history of mood disorder and
stressful life events (18–20), emerging studies on high-risk youth
described a series of prodromal symptoms (21–23), therefore
supporting the notion of a traceable at-risk stage.
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Moreover, at that moment there was increasing evidence
emerging from clinical, neuroimaging and neurocognitive
studies that supported a progressive and deteriorating course
of bipolar disorder (11). For instance, it had been reported
that inter-episode periods were longer after the first episodes,
but tended to shorten as the number of episodes increased
(24). It had also been found that longer duration of the
illness with multiple relapses seemed to be associated with
increased medical comorbidities and increased suicidal risk
(25). Furthermore, available evidence suggested that response
to psychological and pharmacological treatments might not be
the same over the illness course (26–29). Response to lithium,
for example, seemed to be better if started early after illness
onset (30, 31) and before multiple relapses had taken place (32).
The number of episodes had also been found to be related to
neuroanatomic changes in the brain (33). In 2002, Strakowski
et al. (33) described increased lateral ventricular size in bipolar
patients with multiple manic episodes, but not in first-episode
patients. Likewise, evidence supported that a longer duration
of illness and a larger number of episodes was associated
with cognitive dysfunction which, in turn, seemed to involve a
worse clinical course and functional disability (34). The authors
hypothesized that all those alterations observed in the later
stages of bipolar disorder were a consequence of progressive
changes in the central nervous system due to subsequent mood
episodes (6, 7). This phenomenon was called neuroprogression
(6). Berk and colleagues suggested several possible pathways
involved in neuroprogression including inflammation, oxidative
stress, neurotrophins imbalance, mitochondrial dysfunction and
epigenetics (6, 7).
Drawing all this evidence together, Berk and colleagues
described a staging model with a special focus on the initial
phases of the disease and number of episodes (Table 1).
The Ascendance of Biological Psychiatry:
Kapczinski et al. (12)
Kapczinski and colleagues’ model appeared at a moment when
biological explanations gained prominence and risk phases were
explained based on a gene-environmental (GxE) approach (12).
For early stages, the GxE perspective suggested that individual
genetic differences determine distinct resilience or vulnerability
to environmental stress, placing individuals at different risk
levels to develop bipolar disorder (35, 36). For late stages, this
approach suggested that every individual has a different neuronal
resilience to the deleterious effect of repetitive mood episodes
(12). Along this line, Kapczinski et al. (37) adapted McEwens’
notion of allostatic load to bipolar disorder (38). This concept
implies that the interaction of neuroprogressive changes, somatic
comorbidities and substance abuse leads to a dwindling resilience
to life stress, especially if coping skills are poor (37). Hence,
according to Post’s kindling hypothesis (36), while stressful life
events are an important trigger for first affective episodes, later
on the course of the disease recurrences might take place without
a clear environmental factor (37).
At that time, studies focusing on the pathophysiology of
bipolar disorder reported a deregulation of oxidative and
inflammatory pathways in bipolar disorder, especially during
mood episodes (39–43), which came with a decrease in
neurotrophic factors, like brain-derived neurotrophic factor
(BDNF) (44–46). Importantly, it was also described that levels
of neurotrophins, oxidative and inflammatory markers differed
depending on illness stage (47, 48). For instance, compared to
controls, the serum levels of the pro-inflammatory cytokine IL-
6 were increased both in the early and late stages of bipolar
disorder, while levels of BDNF and the anti-inflammatory
cytokine IL-10 were decreased in late stages (meaning patients
with 10–20 years of illness duration) but not in early stages (47).
TNF-alpha levels appeared to be elevated throughout the illness
course but were even higher in later stages (47). In addition,
some parameters of oxidative stress, such as 3-nitrotyrosine,
were found to be altered in the early and late stages of bipolar
disorder, but not in controls (48). The activity of key enzymes
in the glutathione pathway was found to be increased in late-
stage patients compared with early-stage patients and controls
(48). Hence, these data supported the hypothesis presented by
Berk and colleagues indicating that neurotrophic, inflammatory
and oxidative pathways may be involved in neuroprogression (6).
Furthermore, neuroimaging findings also supported the concept
of neuroprogression, as although some cerebral structures were
shown to be already altered in early stages (49–51), longitudinal
studies indicated that patients with repetitive mood episodes
showed a progressive brain gray matter loss (52, 53). All these
findings implied the identification of putative biomarkers that
could be useful to distinguish between patients in early and late
stages of bipolar disorder (54).
Psychosocial functioning was also gaining momentum as
an outcome measure in bipolar disorder, since it had been
demonstrated that symptomatic recovery is not equivalent
to functional recovery (55). Psychosocial functioning involves
domains such as work and education, leisure time, social and
affective relationships or independent living (56), and it can
be negatively affected by clinical variables and neurocognitive
impairments (57).
Accordingly, Kapczinski and colleagues presented a model
based on functioning that, moreover, incorporated cognition and
biomarkers (12) (Table 1).
A Broader Vision of Bipolar Disorder: Duffy
(13)
Duffy proposed a more integrative clinical staging model which
described the natural history of bipolar disorder according to
illness subtypes: the classical form of bipolar disorder (alternant
manic-depressive episodes) vs. the broader bipolar spectrum
(13). Duffy claimed that, while the classical form of bipolar
disorder tended to follow the progressive course described in
previous staging models (i.e., a recurrent and deteriorating
course with an increasingly shorter inter-episodic period),
other subtypes of bipolar disorder might present a different
evolution (13). Evidence, for instance, supported that lithium
non-responders showed a more chronic course and a higher-
risk of non-affective disorders in family members (58, 59).
Neuroimaging and genetic differences between classical lithium
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responsive bipolar patients and lithium non-responsive bipolar
patients were also reported (60, 61). Moreover, her model was
supported by longitudinal data showing differences between
offspring of lithium responders and lithium non-responders
regarding the prodromal period and longitudinal course of
bipolar disorder. Offspring of lithium responders had a personal
history of anxiety and sleep disorders before illness onset and,
once bipolar disorder was established, tended to show an episodic
remitting course with good response to lithium (62–64). In
contrast, offspring of lithium non-responders manifested higher
rates of early developmental alterations, attention deficits and
cluster A personality traits (62–64) and, for those who developed
bipolar disorder, illness course tended to be more torpid and
response to anticonvulsant or atypical antipsychotic seemed to
be better than to lithium (63). Thus, Duffy aimed to present an
integrative stagingmodel that describes the expected longitudinal
course of classical episodic bipolar disorder and of bipolar
spectrum disorder (Table 1).
WHEN STAGING IS NOT ENOUGH
Although different staging models have been proposed in
bipolar disorder over the last 25 years, they still need to
be better operationalized and validated by empirical research
(14). The idea behind the different staging models is to allow
defining, for every individual, the extent of illness progression
in the moment of the evaluation (65). This can help to refine
diagnosis, adjust prognosis and choose the best treatment
according to illness stage (66). In this regard, authors have
suggested some treatment approaches adapted to every stage:
most models agree that prodromal stages would benefit from
interventions targeted toward reducing stressors and increasing
coping skills; early stages would benefit from patient and family
psychoeducation and simpler pharmacological regimens; while
mid-stages would needmore intensive psychotherapies andmore
complex pharmacotherapies (12, 15). Clozapine or functional
remediation therapies would be reserved for more chronic stages
(15). Some individuals with highly refractory illness may need
more “palliative” approaches focusing on reduction of side-
effects and unnecessary polypharmacy, limited symptom control,
identifying and targeting psychological and social problems, and
setting realistic goals to aim for the best quality of life for people
and their families within the envelope of their disability (67).
However, even if the staging model proposes stage-targeted
treatments that might provide a better clinical outcome with
less side effects, there are still differences among the patients
of a particular stage. In consequence, “standard stage-adapted
treatments” may not be useful for every patient at a particular
stage (15) and increasing the level of precision in every stage
would be desirable in order to achieve an even more personalized
way of approaching the patient (16) (Figure 1).
FIGURE 1 | From DSM/ICD to precision staging models. The DSM/ICD model classifies patients into particular conditions according to clinical-based criteria.
DSM/ICD diagnosis can be refined by course specifiers. The staging model allows placing the patient in a particular stage according to the extent of illness
progression, starting from at-risk stages (stage 1) to more chronic ones (stage 3). However, there can still be differences between patients within a particular stage. A
precision staging model would then use the new advances on precision medicine to better characterize the patients and offer them a more personalized treatment.
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FROM STAGING TO PRECISION STAGING
MODELS
The aim of precision psychiatry is to offer the patient tailored
medical decisions and treatments (68). For that purpose,
precision psychiatry needs to integrate biographical, clinical
and biological information regarding each individual (69). In
addition, precision psychiatry is envisaged to benefit from
the coming advances in technological, data, and computer
science to aid diagnostic processes and treatment provision. A
precision stagingmodel would ideally incorporate all these recent
progresses into the appropriate stage (Table 2).
Many advances in precision medicine are related to genomics.
Genomics have led to improvements in staging models in
some branches of medicine, especially cancer (70). However,
psychiatric disorders are genetically complex conditions and
their genetic underpinnings remain to be determined. Still,
international consortia that comprise samples from several
countries have brought some light on risk loci associated
with bipolar disorder (71, 72). These collaborative genome-
wide association studies (GWAS) allow overcoming replication
difficulties often seen in genetic studies due to small sample sizes.
One of these studies analyzed genomic data on a sample of 40,000
bipolar patients and replicated the discoveries of previous GWAS
studies regarding several single-nucleotide polymorphisms
(SNPs) statistically associated with the disease, including variants
within the genes CACNA1C, ANK3, MAD1L1, and SYNE1
(73). Two new risk loci were also identified (73). Moreover, the
Psychiatric Genomics Consortium has recently identified specific
loci that distinguish between bipolar disorder and schizophrenia
(74). Genetic markers promise to be valuable at the earliest stages
of bipolar disorder, as the main aim of mental health approaches
at at-risk and early stages is to predict disease vulnerability and
make accurate diagnosis. So far, though, little of the advances in
genomics have translated into clinically useful tools.
Besides genetic markers, screening for risk factors and
epigenetic modifications may be another useful tool at at-risk
stages of the disease, given that stressful life events, particularly
childhood trauma, can alter DNA methylation and may increase
the risk of developingmood disorders (75). Concordant with this,
childhood verbal, physical, or sexual abuse has been related to a
worse illness course (76).
Risk calculators are another promising tool for at-risk stages
(77), as the multifactorial and polygenic nature of bipolar
disorder makes it improbable that a single factor can accurately
predict its onset (78). The Pittsburgh Bipolar Offspring Study
group (BIOS) has recently developed a risk calculator to predict
the 5-year risk of bipolar disorder onset in offspring of parents
with bipolar disorder combining dimensional measures of mania,
depression, anxiety, mood lability, psychosocial functioning, and
parental age of mood disorder onset (79). Although their findings
need to be replicated, themodel seemed to be able to predict onset
of bipolar disorder with an area under the curve (AUC) in the
receiver operating characteristic curve analysis of 0.76 and might
be of potential value for youth at ultra-high risk for BD. Machine
learning, a field of computer science that studies and constructs
TABLE 2 | Potential precision staging model in bipolar disorder.
Clinical
stage
Definition Potential precision tools and precision
interventions
Domains to be assessed and general
interventions
At-risk stages Increased risk of severe mood
disorder (e.g., family history,
abuse, substance use)
Asymptomatic or non-specific
symptoms of mood disorder
Individualized evaluation of risk/protective factors
Genetic and epigenetic markers
a) Clinical domain
b) Cognitive domain
c) Functional domain
d) Comorbidities domain:
- Substance use
- Physical comorbidities
- Psychological comorbidities
Prodromal features: ultra-high
risk
Genetic and epigenetic markers
Risk Calculator
Risk biomarkers (molecular, neuroimaging)
Machine learning approaches (risk for bipolar
disorder)
Cognitive enhancers
Early stages First-episode threshold mood
disorder
Genetic markers of treatment response
Epigenetics (illness course)
Biomarkers of treatment response and illness
progression
Machine learning approaches (suicide risk)
mHealth (Psychoeducation, monitoring)
Pharmacotherapy and psychological
interventions adapted to each individual
physical and psychological comorbidities
Mid stages Clinical relapse Pharmacogenetic tests
Biomarkers of treatment response and illness
progression
Machine learning approaches (suicide risk)
mHealth (psychoeducation, monitoring)
Functional remediation tailored to patients’ profile,
cognitive enhancers
Substance use intervention
Late stages Persistent unremitting illness Functional remediation tailored to patients’ profile
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algorithms that can learn from large number of data, find patterns
and make predictions (80), might also be useful to estimate the
individual probability of a particular outcome (80, 81). Mourao-
Miranda et al. (82), for instance, found that machine learning
approaches using functional magnetic resonance imaging (fMRI)
data could differentiate between adolescents genetically at-risk
for mood disorders and healthy controls with a 75% accuracy
(sensitivity = 75%, specificity = 75%). Moreover, those at-risk
adolescents who developed an anxiety or depressive disorder at
follow-up showed significantly higher predictive probabilities,
therefore suggesting that predictive probabilities could be used
as a score to predict which at-risk adolescents would develop a
mood disorder in the future (82).
Early and middle stages of bipolar disorder may benefit
from progress in the field of pharmacogenomics. This is the
study of genetic variations that affects individual response to
drugs and vulnerability to adverse effects (83). After the first
acute episode, selecting the best treatment for the patient,
both in terms of efficacy and tolerability is a necessary but
complex task. International consortiums in genetics, such as
the International Consortium of Lithium Genetics (ConLiGen)
(71), have worked to disentangle genetic variants associated
with treatment response, mainly response to lithium. In 2016,
the ConLiGen consortium uniformly phenotyped 2,563 bipolar
patients and reported a genome-wide significant association
with a locus of four linked SNPs on chromosome 21 and
lithium response (84). Another recent GWAS performed by
the ConLiGen consortium displayed that bipolar patients
with a low genetic load for schizophrenia showed a better
response to lithium (85). Pharmacogenetic screening for hepatic
cytochrome P450 genetic polymorphisms can also be helpful
in the near future to predict tolerability and side effects of
psychiatric treatments (86). While the precise patient profile
that would benefit from these tests remains to be elucidated,
pharmacogenetic tests are kept for selected patients with unusual
patterns of drug response or unexpected adverse reactions
(83, 87).
Less progress has been made in the field of biological
markers in the last few years and data on molecular and
neuroimaging biomarkers is still contradictory and limited by
the heterogeneity between studies and the poor specificity of
the putative biomarkers (88). Although evidence is not yet
compelling, some biological markers have been suggested to be
associated with increased risk of conversion to bipolar disorder,
and therefore may be useful when assessing subjects at at-
risk stages. fMRI studies report that frontal hyperactivation
during working memory paradigms may be associated with
genetic risk for bipolar disorder (89, 90). In more established
stages, neuroimaging might be useful to monitor treatment
response (91). Also, a preliminary study using a voxel-
based morphometry-pattern classification approach was able
to distinguish between patients with unipolar and bipolar
depression based on structural gray matter differences (92).
Studies on biological markers have also suggested that peripheral
concentrations of BDNF could be used to discriminate unipolar
depression from bipolar depression (93, 94), but evidence is not
clear (95). This would be of the utmost importance in the earliest
stages of the disease, considering that bipolar disorder is often
misdiagnosed since the index episode is frequently depressive. In
consequence, patients are treated with antidepressants and the
introduction of a mood stabilizer is delayed until the first manic
episode is detected, whichmay negatively affect illness course and
prognosis (8).
Regarding other molecular markers, hypothalamic-pituitary-
adrenal (HPA) axis dysfunction is thought to be one of the
pathways involved in neuroprogression in bipolar disorder (96),
but it has also been suggested to be a useful trait marker in
high-risk individuals (97, 98). Alterations in neurotransmitters
transporters have been suggested as markers of bipolar disorder
(96), but there is no evidence on changes in neurotransmitters
according to illness stage. Regarding later stages of bipolar
disorder, recent studies have reported higher levels of TNF-alpha
and IL-6 in late stages of bipolar disorder (99, 100). Similarly,
Soeiro-de Souza and colleagues described that patients with
recurrent episodes showed increased oxidative and inflammatory
markers, which were related to the number of manic episodes
(101). Further, increased inflammation, increased oxidative stress
and reduced telomere length have been suggested as possible
mechanistic links between psychiatric diseases like bipolar
disorder and other systemic diseases, such as endocrine or
cardiovascular diseases (102–105). Hence, the identification of a
deregulation on those pathways related to both psychiatric and
somatic diseases may have therapeutic implications (106). For
instance, bipolar patients exhibiting persistently increased low-
grade inflammation (107) might benefit from anti-inflammatory
treatment strategies and from periodic screening of systemic
conditions like metabolic syndrome (106). Considering these
data, screening for physical comorbidities seems especially
important in middle and late stages of the disease, albeit
protecting against complications like physical comorbidities or
substance abuse should be a priority at every stage of the disease.
Cognition is another important domain that needs an
individualized evaluation throughout all the stages of bipolar
disorder (108). On one hand, cognitive reserve, defined as the
ability of a brain to cope with brain pathology in order to
minimize symptoms (109), may be useful in early stages to
predict neurocognitive performance in patients with bipolar
disorder (110), as it has been found that lower estimated
cognitive reserve is associated with worse performance in
neuropsychological tests and more functional impairment (110,
111). Similarly, a recent study on first-episode psychosis has
found that those patients with affective psychosis with a greater
cognitive reserve showed a higher socioeconomic status, better
functioning and greater verbal memory performance (112). This
study also emphasizes the need to explore the impact of specific
interventions, like physical activities and hobbies, on cognitive
reserve, since it could be useful to guide the development of
personalized treatment programs (112). Therefore, cognitive
enhancing strategies might be key in the early stages and not
necessarily in the late stages of the disease. On the other
hand, evidence points to a heterogeneous cognitive profile in
bipolar patients both in “cold” and “hot” cognition (113–115).
The presence of such heterogeneous cognitive profiles among
patients with bipolar disorder might be taken into account to
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design more tailored cognitive remediation therapies adapted
to each individual needs (116–118). Cognitive deficits may
also limit long-term psychosocial functioning, which means
that patients with greater cognitive impairment are more likely
to experience poorer outcomes. Previously, we showed that
patients in stage I and healthy controls had similar functioning
patterns. In addition, a strong linear association was found
between functioning and clinical stages, suggesting a progressive
functional decline from stage I through to stage IV of bipolar
disorder. These findings provide further support to the clinical
staging model in bipolar disorder, indicating that bipolar patients
lie on a continuum of disorder progression ranging from periods
of favorable functioning to others of incomplete functional
recovery (118). The link between variables related to the course
of the illness, cognitive deficits and functioning suggests that
early intervention is crucial to prevent illness progression and
to improve cognitive/functional outcome. Some studies have
also found different profiles of psychosocial functioning in
patients with bipolar disorder, which should also be taken into
consideration in the framework of a personalized approach (3,
119).
All these advances should complement regular clinical
practice, which already contains elements of staging and
precision psychiatry. The assessment of the patient’s particular
symptoms, such as his/her distinctive early signs of relapse,
predominant polarity (i.e., the “tendency” to present more
depressive or manic relapses) (120) or individual suicide risk
(121) is regularly done in clinical settings and is essential to
monitor the patient evolution and guide treatment selection.
Technological advances used in everyday life, encompassed in
the concept of mobile Health (mHealth), might be a valuable
tool to help clinicians to collect individualized data on illness
course and monitor illness progression (122). For instance,
changes in activity, geolocation or sleep patterns may help to
detect early signs of mood relapse (123, 124). Additionally,
smartphone apps can be used to empower patients with bipolar
disorder to detect prodromal symptoms of relapse by providing
them personalized psychoeducational messages (125, 126). New
methods like machine learning approaches might also be useful
in the future to help predict suicide risk (127, 128).
DISCUSSION
In this review we describe the evolution of the staging model
in bipolar disorder since its introduction into psychiatry. The
first staging models in bipolar disorder were initially based on
evidence derived from cross-sectional studies, but longitudinal
studies and data on neuroimaging, peripheral biomarkers,
cognition, psychosocial functioning, and prodromal symptoms
have successively enriched the staging models (66). We have also
described several elements of precision psychiatry that could be
incorporated in future precision staging models.
The main advantage of staging and precision medicine is the
recognition that a reductionist clinical approach based on the
presence or absence of a series of symptoms is not enough to
design an adequate therapeutic strategy. These symptoms need
to be considered in the light of the illness progression and, most
importantly, of the patient’s own clinical evolution. For instance,
the presence of a switching or non-switching pattern should
be considered when evaluating a patient, as it has prognostic
implications and therefore might impact staging. As highlighted
in a review by Salvadore et al. (129), patients showing a switching
pattern [i.e., patients showing a “sudden transition from a mood
episode to another episode of the opposite polarity” (129)]
usually spend less time in remission, show higher comorbidity
rates and substance abuse and are at a higher risk of suicide
attempt (129). While mood symptoms will of course still be
the cornerstone of bipolar disorder diagnosis, other elements
should be likewise considered as they can be as informative as
clinical symptoms (9, 10, 12, 15). As such, everyday difficulties,
cognitive complains, substance abuse or comorbidities can be
markers of illness severity or stage specifiers and merit an
individualized assessment and treatment. Social and personal
losses due to the illness and previous personality should also
be included in a standard evaluation throughout the stages and
be given the attention they deserve (10). Patients’ insight and
perception of the disease should be carefully assessed, as these
are important prognosis and therapeutic factors, especially in
early stages (8). Medication load, treatment satisfaction, and
compliance should be also carefully assessed, as it might influence
disease progression. While this way of approaching the patient
is naturally adopted by most clinicians and many guidelines, it
remains underrepresented in diagnostic manuals (5). In any case,
this approach is more in line with theWorld Health Organization
definition of health: “Health is a state of complete physical,
mental and social well-being and not merely the absence of
disease or infirmity”1. The inclusion of self-report measures of
well-being in research and clinical care in bipolar disorder may
contribute to take into consideration the patient’s perspective
when assessing the efficacy and usefulness of pharmacological
and psychological interventions (130).
Another important point of clinical staging is the assumption
that prodromal phases of the disease can be also identified
and targeted. The possibility of making an early diagnosis
radically changes the way how bipolar disorder in particular, and
psychiatric diseases in general, have hitherto been managed. At-
risk stages are rather non-specific, though. In consequence, the
prodromal period has also been preferably defined as “at risk
mental states” (17), as a prodrome is defined as “any symptom
that signals the impending onset of a disease” (131) and evidence
does not support this definition. On one hand, data from the field
of ultra-high risk in psychosis shows that disease onset is not
deterministic and a significant proportion of the at-risk youth
show a remission of these early symptoms (132). On the other
hand, these early symptoms are not specific to any disease but can
progress into several possible psychiatric conditions (64). In the
absence of specific genetic markers for bipolar disorder or very
precise risk calculators, transdiagnostic preventive interventions
aimed to reduce stress, educate on mental-well-being and
prevent substance abuse are preferable at these at-risk stages
(133). Implementing early interventions that include enhancing
1WHO. http://apps.who.int/gb/bd/PDF/bd47/EN/constitution-en.pdf?ua=1. 1946
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cognitive reserve by increasing mental stimulation (reading and
cognitive exercises), introducing physical exercise and leisure
activities or building social skills and social interaction, may
provide a set of skills that can help to cope better with the disease
(134–136). This kind of preventive interventions or “positive
habits” could even be implemented at school or primary care,
which could help to reduce stigma on mental health by educating
the population on the importance of taking care of mental well-
being (133).
In this regard, it has been suggested that a transdiagnostic
staging model might be more adequate for the study of at-
risk phases, while disorder-specific models are more useful once
the fully-develop disorder emerges (15). It is necessary to bear
in mind that psychiatric disorders are dynamic and clinical
symptoms may evolve over time, requiring a change in diagnosis
(137). Nevertheless, the general staging approach supported by
stage specifiers should still be useful to assess illness severity
regardless of changes in DSM or ICD diagnosis.
Biomarkers also face the problem of lack of specificity.
Alterations in the inflammatory or oxidative systems have been
found across several psychiatric and medical diagnoses (138).
Again, biomarkers could be more stage-specific than illness-
specific and be conceived as an additional tool for the assessment
of illness risk or treatment outcome. Low sensitivity and
replicability seems a bigger handicap. Moreover, most published
data on biomarkers are based on the currently commercially
available ELISA kits, which is also a limiting factor. State-of-the-
art techniques widely used in precision medicine might help to
overcome these limitations. A multi-omic approach, meaning
using genomic, epigenomics, transcriptomics, proteomics,
metabolomics, metagenomics, and lipidomics data, combined
with environmental information gathered, for instance, through
mobile devices, could help to identify more sensitive biomarkers
panels to guide diagnosis and treatment choice (69). However,
as these “omic” platforms cannot be used in regular clinical
practice, the potential discoveries arising from these platforms
need to be translated into an immuno-based assay, which is
a more viable option. New strategies with a more integrative
approach between clinical factors and biological markers are
being proposed in biomarker research of lithium response, which
are expected to shed some light on precision drug prescription
(139).
Precision in psychiatry implies embracing the
multifactoriality of psychiatric diseases and the need to
incorporate in the patient’s assessment a range of biological
and environmental factors that interact with each other in a
dynamic way. Moreover, the biological and environmental
factors involved in illness onset and progression are particular
to every patient, as it is the way they interact (17). The use
of personal devices to monitor the trajectories of patients at
anytime and anywhere might help to deepen our knowledge on
the complex interaction between biological and environmental
factors. They can also allow evaluating less studied markers, such
as sleep or chronobiological markers, which may turn out to be
very informative (140). Moreover, further studies on epigenetics
or mitochondrial genomes might identify novel factors involved
in this complex disease (141). Similar to what is being developed
in the field of psychosis, research on bipolar disorder could
benefit from consortia sharing data to develop machine learning
algorithms to help the prediction of bipolar disorder onset
(17, 142).
A major limitation of current staging models is the absence
of an agreement on the definition of stages. Moreover,
operationalized cut-off points are lacking, probably due to the
lack of longitudinal studies assessing patients according to
stages, the absence of clear and reproducible neurobiological
markers defining every stage and the intrinsic heterogeneity
of psychiatric illnesses (15, 16, 143). Therefore, the current
proposed models of staging are mainly theoretical and need
to be validated for the moment. Additionally, participants of
the available studies assessing differences between early and late
stages of bipolar disorder include subjects attending specialized
clinics, hence probably representing more severe forms of bipolar
disorder (16). Moreover, it should be noted that precision
medicine is still in its early beginnings, meaning that findings
on genomics, genetic markers, and epigenetics are preliminary
and need to be replicated before being integrated in any model of
classification.
Until more solid information is available on the biology of the
disease, though, the staging models can be based on pragmatic
variables, like number of episodes and impact on cognition and
functionality. A staging system based on characteristics that can
be easily measured allows to standardize it and make it available
and applicable in a broader number of clinical settings and
countries worldwide (144).
Regardless of what the future brings, personalized medicine
means “patient-centered care,” therefore the choice among those
new diagnostic techniques or treatments should be subject to
a consensus between the clinician and the patient, especially
considering the new ethical challenges that precision psychiatry
brings with it (145). While psychiatrists can offer their expertise,
patients opinions and preferences should play a central role in
treatment decisions through shared decision-making (145).
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